Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis
- PMID: 19407667
- DOI: 10.1097/gme.0b013e3181a1824e
Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis
Abstract
Objective: There is increasing evidence to suggest that ossein-hydroxyapatite complex (OHC) is more effective than calcium supplements in maintaining bone mass. The aim of this meta-analysis was to determine whether OHC has a different clinical effect on bone mineral density (BMD) compared with calcium carbonate (CC).
Methods: A meta-analysis of randomized controlled clinical trials was carried out to evaluate the efficacy of OHC versus CC on trabecular BMD. We identified publications on clinical trials by a search of electronic databases, including MEDLINE (1966-November 2008), EMBASE (1974-November 2008), and the Cochrane Controlled Clinical Trials Register.The primary endpoint was percent change in BMD from baseline. Data were pooled in a random-effects model, and the weighted mean difference was calculated. A sensitivity analysis that excluded trials without full data was performed.
Results: Of the 18 controlled trials initially identified, 6 were included in the meta-analysis. There was no significant heterogeneity among the included trials. The percent change in BMD significantly favored the OHC group (1.02% [95% CI, 0.63-1.41], P < 0.00001). These results were confirmed in the sensitivity analysis.
Conclusions: OHC is significantly more effective in preventing bone loss than CC.
Similar articles
-
Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial.J Reprod Med. 1999 Jul;44(7):601-5. J Reprod Med. 1999. PMID: 10442322 Clinical Trial.
-
Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial.Menopause. 2008 Nov-Dec;15(6):1132-8. doi: 10.1097/gme.0b013e318170af33. Menopause. 2008. PMID: 18791486 Clinical Trial.
-
Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss.Climacteric. 2020 Jun;23(3):252-258. doi: 10.1080/13697137.2019.1685488. Epub 2019 Nov 21. Climacteric. 2020. PMID: 31747785
-
Use of ossein-hydroxyapatite complex in the prevention of bone loss: a review.Climacteric. 2015 Feb;18(1):29-37. doi: 10.3109/13697137.2014.929107. Epub 2014 Aug 17. Climacteric. 2015. PMID: 24893923 Review.
-
Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery.Am J Gastroenterol. 2009 Jun;104(6):1548-61; quiz 1547, 1562. doi: 10.1038/ajg.2009.176. Epub 2009 Apr 28. Am J Gastroenterol. 2009. PMID: 19491872 Review.
Cited by
-
New Horizons for Hydroxyapatite Supported by DXA Assessment-A Preliminary Study.Materials (Basel). 2022 Jan 26;15(3):942. doi: 10.3390/ma15030942. Materials (Basel). 2022. PMID: 35160888 Free PMC article.
-
Acceleration of Bone Fracture Healing through the Use of Bovine Hydroxyapatite or Calcium Lactate Oral and Implant Bovine Hydroxyapatite-Gelatin on Bone Defect Animal Model.Polymers (Basel). 2022 Nov 9;14(22):4812. doi: 10.3390/polym14224812. Polymers (Basel). 2022. PMID: 36432941 Free PMC article.
-
Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study.Clin Drug Investig. 2011 Dec 1;31(12):817-24. doi: 10.1007/BF03256920. Clin Drug Investig. 2011. PMID: 22035462 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical